| Compound | TB-500 (Thymosin Beta-4 Fragment) |
|---|---|
| Category | Actin-binding thymosin fragment |
| Class | Healing and Anti-Inflammatory Peptides |
| Evidence tier | Preclinical |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
TB-500 (Thymosin Beta-4 Fragment) is catalogued here as a actin-binding thymosin fragment and graded at the "Preclinical" evidence tier. The evidence base for this compound is dominated by animal and cell-culture studies. Mechanism may be plausible; human benefit and safety are unestablished.
A synthetic fragment of thymosin beta-4, an actin-binding protein involved in cell migration and wound repair. Marketed products may contain the fragment or, in some cases, the full-length protein — a labeling inconsistency worth noting.
Mechanism of Action
Thymosin beta-4 participates in actin polymerization, cell migration, and angiogenesis. Proposed healing effects in animal models build on these functions, but the translation to controlled human outcomes has not been demonstrated.
Research and Evidence
Evidence is predominantly preclinical, spanning corneal, cardiac, and dermal wound models. No adequately powered human trials have been published, and thymosin products have a history of regulatory and quality issues.
Safety and Side Effects
Human safety data are lacking. Product quality in unregulated channels is inconsistent, and the actual content of vials labeled "TB-500" varies. Anyone subject to anti-doping rules should verify the current status of thymosin beta-4 with the applicable authority.
Frequently Asked Questions
What is the evidence tier of TB-500 (Thymosin Beta-4 Fragment)?
TB-500 (Thymosin Beta-4 Fragment) is graded "Preclinical" on this site. The evidence base for this compound is dominated by animal and cell-culture studies. Mechanism may be plausible; human benefit and safety are unestablished.
Is TB-500 (Thymosin Beta-4 Fragment) an approved medicine?
No. Preclinical means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for TB-500 (Thymosin Beta-4 Fragment)?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — search for thymosin beta-4 studies. [source]
Evidence tier: Preclinical · Last reviewed: 2026-09-05 · Sources cited below.